PRNewswire
A Drug with Superior Efficacy to Avastin at Improving Visual Acuity When Used with Laser Photocoagulation Would Earn a 20 Percent Patient Share, According to a New Report from Decision Resources
WALTHAM, Mass., June 26 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms focusing on pharmaceutical and
healthcare issues, finds that Genentech/Novartis's Lucentis will become the
Decision Resources' proprietary clinical gold standard by 2011 because of its
ability to generate higher total sales in the United States and Europe due to
its higher price. Although ophthalmologists perceive Lucentis as offering
comparable efficacy to the current clinical gold standard, Avastin, Lucentis
exhibits slightly greater affinity than Avastin to vascular endothelial growth
factor (VEGF). If data continue to be positive for Avastin however, it will
likely maintain a strong patient-share advantage over Lucentis and others
because of its lower price.
The new report entitled Diabetic Retinopathy: Future Demand to Be Driven
by Agents that Improve Visual Acuity also finds that a therapy that is more
effective than Avastin at improving visual acuity when used in conjunction
with laser photocoagulation therapy, would earn a 20 percent patient share in
the treatment of diabetic retinopathy. Surveyed ophthalmologists indicate that
an improvement -- not maintenance -- in visual acuity is fast becoming the
target outcome of treatment for diabetic retinopathy including for patients
with diabetic macular edema.
"Ophthalmologists we surveyed indicated that they would prescribe agents
that fulfill either the Minimal Acceptable or Major Achievement profiles to 20
percent of their diabetic retinopathy patients," said Caroline Gates, B.Sc.,
analyst at Decision Resources. "Given the price set for each of the target
product profiles and the forecasted size of the diabetic retinopathy patient
population in 2011, a 20 percent patient share would result in sales of $42.7
million for an agent fitting the Minimal Acceptable drug profile and $320.3
million for an agent fitting the Major Achievement profile."
About the Report
Diabetic Retinopathy: Future Demand to Be Driven by Agents that Improve
Visual Acuity is a DecisionBase 2008 report from Decision Resources.
DecisionBase 2008 combines market forecasts with clinical and commercial end
points to assess market share projections in 35 indications. These outputs are
driven by quantitative and qualitative primary research. DecisionBase 2008
provides detailed market share, patient share, and price-per-day projections
for emerging drugs in development. The market share projections are based on
prescriber surveys that compare physicians' expectations of a potential target
product profile with an emerging product profile of the leading drugs in
development.
The report can be purchased by contacting Decision Resources. Members of
the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.